An MMAE-loaded PDL1 active targeting nanomedicine for the precision treatment of colon cancer

Zhang, Zhenqian; Zhang, Honglei; Cui, Li; Wang, Xiaoshuang; Wang, Di; Liu, Zhilin; Zhang, Xuefei; Tang, Zhaohui

doi:10.1039/d3bm00664f

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Book1

Relationship

Self Cite1

Independent4

Authors

Journals

Cited by 5 publications

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A tumor‐targeting nano‐adjuvant for in situ vaccine based on ultrasound therapy

Cui,

Yao,

Xue

et al. 2024

Aggregate

Self Cite

View full text Add to dashboard Cite

Ultrasound‐generated antigens combined with TLR7/8 agonists as adjuvants have demonstrated significant anti‐tumor efficacy as an in‐situ vaccine. However, the use of TLR7/8 agonists can cause severe inflammatory responses. In this study, we present a novel tumor‐targeting nano‐adjuvant termed aPDL1‐PLG/R848 NPs, which are composed of aPDL1 antibody, Fc‐III‐4C peptide linker (Fc‐linker) and poly(L‐glutamic acid)‐grafted‐R848. Under ultrasound irradiation, antigen‐presenting cells activate immune mechanisms in vivo under dual stimulation of in situ antigens and immune adjuvants. The strategy inhibits primary tumor growth and induces a strong antigen‐specific immune memory effect to prevent tumor recurrence in vivo. This work offers a safe and potent platform for an in situ cancer vaccine based on ultrasound therapy.

show abstract